The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Pulmonary Outcome at 1 Year Corrected Age in Premature Infants Treated at Birth With Recombinant Human CuZn Superoxide Dismutase
Abstract
Objective. To examine whether treatment of premature infants with intratracheal recombinant human CuZn superoxide dismutase (r-h CuZnSOD) reduces bronchopulmonary dysplasia and improves pulmonary outcome at 1 year corrected age. Design. Three hundred two premature infants (600–1200 g birth weight) treated with exogenous surfactant at birth for respiratory distress syndrome were randomized to receive either intratracheal r-h CuZnSOD (5 mg/kg in 2 mL/kg saline) or placebo every 48 hours (as long as intubation was required) for up to 1 month of age. Short-term, as well as longer-term pulmonary outcome was assessed. Results. There were no differences between groups in the incidence of death or the development of bronchopulmonary dysplasia (oxygen requirement with an Edwards chest radiograph score of ≥3) at 28 days of life or 36 weeks’ postmenstrual age. r-h CuZnSOD was well-tolerated and not associated with significant increases in any adverse event. At a median of 1 year corrected age, health assessments and physical examinations were performed on 209 (80%) surviving infants, with complete data available on 189 infants. Thirty-seven percent of placebo-treated infants had repeated episodes of wheezing or other respiratory illness severe enough to require treatment with asthma medications such as bronchodilators and/or corticosteroids compared with 24% of r-h CuZnSOD-treated infants, a 36% reduction. In infants <27 weeks’ gestation, 42% treated with placebo received asthma medications compared with 19% of r-h CuZnSOD-treated infants, a 55% decrease. Infants <27 weeks’ gestation who received r-h CuZnSOD also had a 55% decrease in emergency department visits and a 44% decrease in subsequent hospitalizations. Growth measurements and the results of physical examinations were comparable between groups. Conclusions. These data indicate that treatment at birth with r-h CuZnSOD may reduce early pulmonary injury, resulting in improved clinical status when measured at 1 year corrected age. r-h CuZnSOD appears to be a safe and effective therapy that improves pulmonary outcome in high-risk premature infants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
JOBE, A. H., & BANCALARI, E. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.7.2011060 · Cited by 4,795
Shennan, A. T., Dunn, M. S., Ohlsson, A., Lennox, K., & Hoskins, E. M. (1988) · Pediatrics · doi:10.1542/peds.82.4.527 · Cited by 1,254
The New BPD: An Arrest of Lung Development
Jobe, A. J. (1999) · Pediatric Research · doi:10.1203/00006450-199912000-00007 · Cited by 1,013
The STOP-ROP Multicenter Study Group (2000) · Pediatrics · doi:10.1542/peds.105.2.295 · Cited by 660
Flynn, J. T., & Bancalari, E. (2000) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1067/mpa.2000.105823 · Cited by 620
Mice lacking extracellular superoxide dismutase are more sensitive to hyperoxia.
Carlsson, L. M., Jonsson, J., Edlund, T., & Marklund, S. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6264 · Cited by 487
Turrens, J. F., Crapo, J. D., & Freeman, B. A. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111210 · Cited by 480
Adverse Effects of Early Dexamethasone Treatment in Extremely-Low-Birth-Weight Infants
Stark, A. R., Carlo, W. A., Tyson, J. E., Papile, L.-A., Wright, L. L., Shankaran, S., Donovan, E. F., Oh, W., Bauer, C. R., Saha, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101113440203 · Cited by 479
Sohn, A. H., Garrett, D. O., Sinkowitz-Cochran, R. L., Grohskopf, L. A., Levine, G. L., Stover, B. H., Siegel, J. D., & Jarvis, W. R. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.119442 · Cited by 418
Murphy, B. P., Inder, T. E., Huppi, P. S., Warfield, S., Zientara, G. P., Kikinis, R., Jolesz, F. A., & Volpe, J. J. (2001) · Pediatrics · doi:10.1542/peds.107.2.217 · Cited by 369
Cited by
Bronchopulmonary Dysplasia: Executive Summary of a Workshop
Higgins, R. D., Jobe, A. H., Koso-Thomas, M., Bancalari, E., Viscardi, R. M., Hartert, T. V., Ryan, R. M., Kallapur, S. G., Steinhorn, R. H., Konduri, G. G., et al. (2018) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2018.01.043 · Cited by 956
Oxidant and antioxidant balance in the airways and airway diseases
Rahman, I., Biswas, S. K., & Kode, A. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.12.087 · Cited by 727
Kinsella, J. P., Greenough, A., & Abman, S. H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68615-7 · Cited by 454
Gitto, E., Pellegrino, S., Gitto, P., Barberi, I., & Reiter, R. J. (2009) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2008.00649.x · Cited by 291
Metadata
- Authors
- Davis, J. M., Parad, R. B., Michele, T., Allred, E., Price, A., Rosenfeld, W., & for the North American Recombinant Human CuZnSOD Study Group
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2003-03-01
- Volume
- 111
- Issue
- 3
- Pages
- 469-476
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2094000643
- Cited by
- 268
- References
- 22
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pulmonary Outcome at 1 Year Corrected Age in Premature Infants Treated at Birth With Recombinant Human CuZn Superoxide Dismutase. https://app.cochat.ai/papers/10.1542/peds.111.3.469
- The paper
- Davis, J. M., Parad, R. B., Michele, T., Allred, E., Price, A., Rosenfeld, W., & for the North American Recombinant Human CuZnSOD Study Group. (2003). Pulmonary Outcome at 1 Year Corrected Age in Premature Infants Treated at Birth With Recombinant Human CuZn Superoxide Dismutase. Pediatrics. https://doi.org/10.1542/peds.111.3.469
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.